Oncology

Research scientists in laboratory
#Abbie #Antibodies #Antibody-based therapeutics #Cancer research #Collaboration #Immunome #Oncology #Partnership

Collaboration to identify up to 10 novel target-antibody pairs

AbbVie and Immunome have agreed a worldwide collaboration with the aim of discovering up to 10 novel antibody-target pairs arising from three specified tumour types using Immunome’s Discovery Engine.  Steve Davidsen, Vice President, Oncology Discovery Research, AbbVie. “Immunome’s approach has the potential to unlock novel cancer biology and yield multiple… Read More

#Business & Investment #Cancer Research #News

Orange County Convention Centre
#Cancer research #Events #Oncology

AACR meeting will share the latest advances in cancer science

The American Association for Cancer Research (AACR) Annual Meeting 2023 will be held April 14-19 at the Orange County Convention Center in Orlando, Florida. The meeting is the focal point of the American cancer research community, where scientists, clinicians, health care professionals, survivors, patients, and advocates share the… Read More

#News

Research lab
#Cancer research #circular RNAs #Collaboration #Esperovax #Ginkgo Bioworks #High throughput screening #Oncology #Partnership #RNA

Alliance to develop circular RNA-based therapeutics

Esperovax and Ginkgo Bioworks have agreed a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications.   Initially, the companies will work to develop circRNAs harbouring payloads to specifically target colorectal cancer by inducing cell death only in cancerous cells.  CircRNAs represent an… Read More

#Cancer Research #News

Cancer cells
#Brain disease #Cancer research #Cell and gene therapy #CRISPR #CRISPR-Cas9 #Gene editing #Mouse models #Neuroscience #Oncology

Scientists turn cancer cells into anticancer agents

Harvard investigators have developed a new cell therapy approach to eliminate established tumours and induce long-term immunity.   In this early research, Khalid Shah, Professor of Neurosurgery at Harvard Medical School and Brigham and Women’s Hospital, and colleagues tested the vaccine in an advanced mouse model of brain… Read More

#Cancer Research #News #Trending News

Cancer research
#Cancer immunotherapy #Cancer research #Funding #Immunotherapy #Investment #ISA Pharmaceuticals #Oncology #Ophthalmology #Synthetic biology

$5 million to fund trial of therapy for uveal melanoma

Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA Pharmaceuticals’ PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.  Cancer Focus Fund was established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and… Read More

#Business & Investment #Cancer Research #News

Urinary system
#Bicycle Therapeutics #Cancer research #FDA #Oncology #United States

FDA fast-tracks metastatic urothelial cancer treatment

The United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Bicycle Therapeutics’ BT8009 monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer.   BT8009 is a potential first in class Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a protein that… Read More

#Cancer Research #News #Regulatory #Trending News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Cancer drug targets #Cancer research #Collaboration #Oncology #Partnership

AI-powered cancer simulations enable drug targeting

Cancer Research Horizons and biotech company Turbine have announced a partnership to solve complex diseases.   The partnership will utilise Turbine’s Simulated Cells platform to identify target patient populations who could benefit from CDC7 inhibitor therapy with Cancer Research Horizons’ lead compound CRT’2199.   CRT’2199 originates from Cancer Research Horizons’ Therapeutic Innovation. Read More

#Business & Investment #Cancer Research #News

Pancreatic cancer
#Antibodies #Cancer immunotherapy #Cancer research #Immunotherapy #Oncology #Pancreatic cancer #Preclinical investigations

Triple immunotherapy eliminates pancreatic tumours

A novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, has significantly improved anti-tumour responses in preclinical models of pancreatic cancer.  In the study, published in Nature Cancer, researchers at The University of Texas MD Anderson Cancer Center… Read More

#Cancer Research #Editor's Choice #News

Prostate-specific membrane antigen
#Cancer research #Europe #Novartis #Oncology #Prostate cancer

New prostate cancer drug approved in Europe

A new drug based on the active ingredient Lutetium-177 PSMA-617 has been approved by the European Commission for the treatment of metastatic prostate cancer carrying the surface molecule PSMA (prostate specific membrane antigen).   The drug was developed under the leadership of the German Cancer Research Center (DKFZ)… Read More

#Cancer Research #News #Trending News

#Biologics / Biotechnology #Cancer research #Financing #Investment #Oncology #RNA

Biotech company raises $30M to target RNA modifying enzymes

Clinical biotechnology company Storm Therapeutics has successfully completed a USD $30 million Series B financing round.  The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases.  The financing was co-led by existing investors M Ventures,… Read More

#Business & Investment #News

Scientist in laboratory
#Antibodies #Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #Janssen #Leukaemia #Myeloma #Oncology

New trial data revealed in potential myeloma and leukaemia treatments

Jannsen has revealed clinical trial results for its pipeline of products to treat multiple myeloma and leukaemia.  The findings were presented at the American Society of Hematology (ASH) 2022 Annual Meeting taking place in New Orleans, US.  Along with positive Phase… Read More

#Cancer Research #News

Research scientist working in laboratory
#Cancer research #Drug discovery #Oncology #Pharma

Oncology Programme will accelerate cancer drug discovery

Biometrics contract research organisation (CRO) Phastar has joined Lean Life Science’s Oncology Development Programme (ODP2).   The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies.  In collaboration with global pharma companies, Cancer Research… Read More

#Cancer Research #News

#Biologics / Biotechnology #CAR-T #China #CRISPR #Drug discovery #Gene editing #Genetics / genomics #HIV #HPV #Oncology #Pharmacology #T cell activation #The Dose

The Dose: DDW’s drug discovery highlights

DDW highlights the most interesting global news and comments within the drug discovery and development sector this month.   Everyone enjoys a good news story and the drug discovery and development sector is no exception. Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening… Read More

#Exclusive Content

Cancer research lab
#Academic #Cancer #Cancer research #Cancer Research Horizons #Cancer Research UK #Collaboration #Oncology

Academic-industry collaboration extends cancer drug alliance 

Cancer Research UK’s innovation engine, Cancer Research Horizons, and Newcastle University, have agreed an extension of their strategic drug discovery alliance with Astex Pharmaceuticals.  The alliance will continue to focus on the discovery of potential new cancer drugs with associated biomarkers, with the aim of providing an… Read More

#Cancer Research #News

#AI #Cancer #Cancer drug targets #Cancer immunotherapy #Cancer research #Immunotherapy #Oncology #The Institute of Cancer Research #The Royal Marsden NHS Foundation Trust

Scientists will target cancer’s ecosystems under new strategy

Cancer is supported by complex ecosystems within the body which can be disrupted by cutting-edge new treatments and cures, cancer researchers have concluded.  The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have revealed plans to direct research against the cells, signals and… Read More

#Cancer Research #News